Physician profile
Peter J Dee
NPI 1649347055
$49,473.31
in general payments reported to CMS, 2019-2025
47 companies · $8,366 in 2025
The $8,366 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,200 · 2020: $4,302 · 2021: $7,278 · 2022: $7,824 · 2023: $6,054 · 2024: $8,449 · 2025: $8,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,738.20 |
| Education | $131.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,904.07 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Abbvie INC. | $6,277.21 | 2019-2025 | Vraylar, Rinvoq, Creon |
| Novo Nordisk INC | $3,647.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $2,741.02 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $2,510.86 | 2022-2025 | |
| Amgen INC. | $2,194.36 | 2019-2025 | Repatha, Otezla, Tavneos |
| Otsuka America Pharmaceutical, INC. | $1,880.78 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,648.92 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Lilly USA, LLC | $1,321.77 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $1,268.61 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,235.58 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $1,194.59 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,193.65 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $1,147.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,073.38 | 2019-2025 | Jardiance, Synjardy |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $952.40 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Horizon Therapeutics Plc | $900.69 | 2019-2023 | Krystexxa |
| Allergan, INC. | $881.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $743.29 | 2019 | |
| Abbott Laboratories | $741.17 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $732.75 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Eisai INC. | $663.56 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $654.45 | 2020-2024 | Xarelto |
| Lundbeck LLC | $595.96 | 2019-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $594.74 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $591.92 | 2021-2024 | Caplyta |
| Arbor Pharmaceuticals, INC. | $528.99 | 2019-2022 | |
| Pfizer INC. | $501.25 | 2019-2024 | |
| Insulet Corporation | $429.17 | 2024-2025 | Omnipod, Omnipod |
| Genentech USA, INC. | $366.88 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $362.14 | 2021 | |
| Idorsia Pharmaceuticals US INC | $348.89 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $203.13 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $191.47 | 2022 | |
| Ani Pharmaceuticals, INC. | $131.94 | 2025 | Purified Cortrophin Gel |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Axsome Therapeutics, INC. | $118.74 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $118.37 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $116.00 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $115.09 | 2020-2021 | |
| Esperion Therapeutics, INC. | $106.79 | 2021 | |
| Exact Sciences Corporation | $106.12 | 2025 | |
| Dexcom, INC. | $91.75 | 2024-2025 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $71.24 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $65.09 | 2020 | |
| Radius Health, INC. | $42.62 | 2019 | |
| Indivior INC. | $40.43 | 2022-2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.